Back to News
Market Impact: 0.25
Biocon Signs Brazil Pertuzumab Deal With Bahiafarma And Bionovis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTrade Policy & Supply Chain
Biocon signed a partnership agreement with Brazil's Bahiafarma and Bionovis covering Pertuzumab, a monoclonal antibody for HER2-positive breast cancer. The collaboration is intended to advance production of the therapy in Brazil, potentially expanding Biocon's access to the Brazilian oncology market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- CNBC Daily Open: Sanctions, strikes and the road to $100 oil
- Oil extends rally, Brent nears $100/bbl as U.S.-Iran tensions escalate
- Bloomberg Businessweek Daily:Oil Gains on Iran Strikes (Podcast)
- Apple's $2000+ iPhone, Oil Gain Stokes Inflation Fear | Bloomberg Businessweek Daily 9/8/2026
- Carney Plots EU Partnership as Canada PM Hits Back at Trump’s Tariffs
- Dell (DELL) Q2 2027 Earnings Call Transcript